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COMMENT&RESPONSE
Avoidable Blood Transfusions
To the Editor I readwithmuch interest the article byGoel et al,1
titled, “Association of Perioperative Red Blood Cell Transfu-
sions With Venous Thromboembolism in a North American
Registry.” The authors should be congratulated for their ef-
forts to findcauses forpostoperativedeepvein thrombosisand,
eventually,pulmonaryembolism.Theyanalyzeddata fromthe
American College of Surgeons National Surgical Quality Im-
provement Program registry regarding 750 937 patients who
had surgery in 525 hospitals over a 1-year period. They found
that therewas ahigher incidenceof deepvein thrombosis and
pulmonary embolism within 30 days from surgery in pa-
tientswhohadreceivedperioperativebloodtransfusion.About
6.3% of the patients received at least 1 blood transfusion. In a
retrospective analysis, they found that blood transfusionwas
an independent risk factor for thromboembolismanddeepvein
thrombosis.
I have concerns about their study. In the United States,
training programs teach the importance of avoiding unneces-
saryblood transfusions. It is almost adogma, and this is some-
what testified by the low number of patients who received
blood transfusions in their data (6.3%). It is very difficult to
comparepatients retrospectivelywithout anobjective assess-
ment of their general conditions and without the possibility
todeterminewhy thosepatients hadblood transfusions.Data
about preoperative hematocrit level were not available. Goel
et al1 performed retrospectivepropensity scorematching; this
analysis presents many drawbacks when it is not possible to
determine all characteristics of the general status of the pa-
tients.Unfortunately,propensity scorematching impliesmany
inadvertent selection biases.
It is wise to accept the conclusions of Goel et al1 that
blood transfusions carry a significant risk, especially for
other reasons than thromboembolism, like transmission of
HIV, hepatitis C, and other unknown, unpredictable diseases.
Still, I have doubts about the appropriateness of the correla-
tion between blood transfusions and deep vein thrombosis;
I think that the final messages of the authors are of para-
mount importance, and there is the need for clear guidelines
about perioperative blood transfusions. Too often, surgeons
feel much better if the patient’s hematocrit level is in an
acceptable range. National guidelines can support the deci-
sion in difficult clinical situations as well as support a legal
defense in times when all of us are obliged to do more than
required just to avoid future consequences.
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In Reply We thank Sterpetti for his response and close atten-
tion to our study.1 We agree with the author’s assertion that
in the United States, there has been an immense focus on re-
ducing unnecessary blood transfusions, supported by clini-
cal practice guidelines and patient blood management
programs.2 The effect of patient blood management initia-
tives in the United States is evident by recent data showing
nationwide decreases in red blood cell (RBC) and plasma
transfusions.3
Our study aimed to evaluate the association of periopera-
tive RBC transfusions with postoperative new-onset/
progressivevenous thromboembolism(VTE).This studyques-
tion stems frommultiple translational andclinical studies that
have suggested a relationship between transfused RBC and
pathologic thrombosis.4,5 As outlined in our article, multiple
mechanistic pathwayshavebeenhypothesized to explain this
potential association.6 Although Sterpetti questions the ap-
propriateness of our study question, we see value in explor-
ing a potential association that is both biologically plausible
and clinically relevant. It should be noted that this studywas
not intended to or designed to calculate causal effects.
Weconductedasecondaryanalysisofdata fromtheAmeri-
can College of Surgeons National Surgical Quality Improve-
mentProgram,avalidatedandwidely recognizednational reg-
istry for studying surgical outcomes. The registry includes
participation from more than 500 academic and nonaca-
demichospitals.While theprospectivedesignand largesample
size of the registry make the data powerful, these data have
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limitations,aswestated in theDiscussionsectionof thearticle.1
An inherent limitationofanyretrospectiveobservational study
is the inability to account for unmeasured (or unmeasurable)
covariates, regardless of the statistical method used to ana-
lyze the data (eg, multivariate regression or propensity score
matching). For instance, the specific preoperativehealth con-
ditionsand indications forperioperativeRBC transfusionwere
unknown.However, it is noteworthy that the associationwas
observed across a number of surgical subspecialties indepen-
dent of several factors related to severity of illness. We hope
futureprospective studieswill account forpotential confound-
ers that could not be examined in our analysis.
As Sterpetti notes, the study did not provide data on pre-
operative hematocrit levels. For patients with available data,
mean (SD) preoperative hematocrit levelswere 39.8% (4.9) in
the group that did not receive any perioperative RBC transfu-
sion and 33.4% (6.4) in the group that received at least 1 peri-
operative RBC transfusion. Including preoperative hemato-
crit levels as a continuous variable in the fully adjustedmodel
does not affect the findings reported in the primary analysis;
any perioperative RBC transfusion remains significantly
associated with the development of postoperative VTE
(adjusted odds ratio, 2.1; 95% CI, 2.0-2.3) in the overall study
population. Postoperative hematocrit levels are not available
in the registry.
Ultimately, our retrospective study supports the hypoth-
esis thatperioperativeRBCtransfusionsmaybeassociatedwith
development of new or progressive VTE within 30 days of
surgery. These data support the need for prospective studies
as VTE continues to be a public health problem.
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Prehospital Advanced Life Support
for Out-of-Hospital Cardiac Arrest
in Blunt TraumaPatients
To the EditorWe thank Fukuda et al1 for their study analyzing
theassociationofprehospital advanced life support (ALS)with
theoutcomesofout-of-hospital cardiacarrest.Theauthorscon-
clude that ALS by physicians resulted in a higher 30-day sur-
vival than ALS by emergency medical service (EMS) person-
nel and basic life support (BLS).
However, the implications of the study may be over-
stated. First, given the retrospectivedesignof the study, there
aremultiple confounding factors that the authorshavenot ac-
counted for. Thesemainly includepatient demographic char-
acteristics, like age and sex;modifiable predictors of survival
outcomes, like body mass index; general health status as as-
sessedby theAmericanSocietyofAnesthesiologists index;and
comorbidities present, as shown in Table 1.1 Importantly, the
extent of blunt injury (assessed by the Injury Severity Score
or Abbreviated Injury Scale score) and etiology of cardiac ar-
restwerenot evaluated.Amajorpredictorof survivalwas time
toresponse,2whichwasstatisticallydifferentbetweenthevari-
ous cohorts (Tables 1 and 3).1 When comparing between EMS
and physicians, it is pertinent to match their expertise, since
physicians, unlike EMS, may have differing experience and
hence success in providing life support.3 Similarly, many
patientswhosurvive longenough to reach thehospital forALS
by physicians fare better because of other above-mentioned
factors.
In addition to the differing sample sizes between the
various cohorts, the authors do not know how patients were
allocated to these cohorts. This introduces selection and allo-
cation bias, especially since these are decisions guided by
clinical findings. Similarly, patients often receive additional
interventions, so using a composite end point such as 30-day
survival is not necessarily a valid measure of the effective-
ness of either ALS or BLS or who provides it. Instead, a more
immediate assessment of ALS success as well as a compre-
hensive assessment of complications during hospital stay is
necessary. Thus, while the study design improves the gener-
alizability of the results, its decreases the internal validity of
the conclusions.
Nevertheless, we agree and emphasize that the prompt
provisionofALSorBLSby trainedprofessionals is vital for op-
timizingsurvival inout-of-hospital cardiacarrest.Furtherwork
is required to determine if these results are observed in
matched cohorts and, if so, to subsequently incorporate these
findings into treatment guidelines.
Vikram Aakash Khanna, BSc
Swathikan Chidambaram, MBBS, BSc
En Lin Goh, MBBS, BSc
Author Affiliations: School of Medicine, Imperial College London, London,
United Kingdom.
Corresponding Author: Swathikan Chidambaram, MBBS, BSc, School of
Medicine, Imperial College London, South Kensington Campus, Exhibition Road,
London SW7 2AZ, United Kingdom (swathikan.chidambaram12@imperial.ac.uk).
Published Online:November 7, 2018. doi:10.1001/jamasurg.2018.4291
Conflict of Interest Disclosures:None reported.
Letters
jamasurgery.com (Reprinted) JAMA Surgery January 2019 Volume 154, Number 1 95
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita Degli Studi di Roma La Sapienza User  on 04/29/2019
